Therefore, FGF2 signalling seems less efficient in KO/PyMT than in WT/PyMT cells, and KO/PyMT tumour cells appear to have deficits in HSPG-dependent, but not HSPG-independent, mitogenic signalling. The gene discussed is FGF2; the disease is neoplasm.